Australian multicentre trial of streptokinase in acute myocardial infarction.
Australian multicentre trial of streptokinase in acute myocardial infarction.
复制标题
澳大利亚链激酶治疗急性心肌梗死的多中心试验。
DOI：
10.1016/s0140-6736(73)90463-7
复制
发表时间：
1973
期刊：
影响因子：
--
通讯作者：
M. Rosenbaum
中科院分区：
文献类型：
--
作者：
J. Bett;P. Castaldi;G. Hale;J. Isbister;K. H. Mclean;E. O'Sullivan;J. Biggs;C. Chesterman;J. Hirsh;I. McDonald;J. Morgan;M. Rosenbaum
在一项多中心对照试验中，517例24小时内临床诊断为心肌梗死的患者被送入冠心病监护室，随机分配接受链激酶、肝素和华法林治疗（264例）或仅使用抗凝剂治疗（253例）。在回顾性分析中发现两组具有可比性。链激酶治疗组3个月内死亡26例（9.8%），对照组32例（12.6%）。这种差异在统计上并不显著。结果表明，链激酶对60岁以上、既往有梗死史和皮尔预后评分超过17分的患者有益处。虽然这些数字太小，这些差异在统计上不显着，但试验仍在继续。3个月时心绞痛和心力衰竭的发生率没有差异。
In a multicentre controlled trial 517 patients with the clinical diagnosis of myocardial infarction within the preceding 24 hours were admitted to coronary-care units, and allocated at random to receive streptokinase followed by heparin and warfarin (264 patients) or anticoagulants only (253 patients). On retrospective analysis the groups were found to be comparable. 26 (9·8%) of those treated with streptokinase and 32 (12·6%) of those in the control group died within 3 months. This difference is not statistically significant. The results suggest that streptokinase benefits those over 60 years of age, those with a history of past infarction, and those with a Peel prognostic score over 17. Although the numbers are too small for these differences to be statistically significant the trial is continuing. There was no difference in the incidence of angina or heart-failure at 3 months.